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Abstract
Aims/hypothesis Diabetes is the leading cause of kidney disease worldwide. There is limited information on screening, treatment
and control of kidney disease in patients with diabetes in low-to-middle-income countries (LMICs).
Methods The International DiabetesManagement Practices Study is an ongoing, non-interventional study of clinical profiles and
practices among patients receiving outpatient care mainly by internal medicine physicians and endocrinologists in LMICs. We
examined screening, prevalence, treatment and control of kidney disease across seven waves (W) of data collection between 2005
and 2017.
Results Among 15,079 patients with type 1 and 66,088 patients with type 2 diabetes, screening for kidney disease increased
between W2 and W3 followed by a plateau (type 1 diabetes: W2, 73.7%; W3, 84.1%; W7, 83.4%; type 2 diabetes: W2, 65.1%;
W3, 82.6%; W7, 86.2%). There were also decreasing proportions of patients with microalbuminuria (type 1 diabetes: W1,
27.1%; W3, 14.7%; W7, 13.8%; type 2 diabetes: W1, 24.5%; W3, 12.6%; W7, 11.9%) and proteinuria (type 1 diabetes: W1,
14.2%; W3, 8.7%; W7, 8.2%; type 2 diabetes: W1, 15.6%; W3, 9.3%; W7, 7.6%). Fewer patients were reported as receiving
dialysis for both type 1 diabetes (W2, 1.4%;W7, 0.3%) and type 2 diabetes (W2, 0.9%;W7, 0.2%) over time.While there was no
change in mean HbA1c or prevalence of diagnosed hypertension (type 1 diabetes: W1, 22.7%; W7, 19.9%; type 2 diabetes: W1,
60.9%; W7, 66.2%), the use of statins had increased among patients diagnosed with dyslipidaemia (type 1 diabetes: W1, 77.7%;
W7, 90.7%; type 2 diabetes:W1, 78.6%;W7, 94.7%). Angiotensin II receptor blockers (type 1 diabetes:W1, 18.0%;W7, 30.6%;
type 2 diabetes: W1, 24.2%;W7, 43.6%) were increasingly used over ACE inhibitors after W1 (type 1 diabetes: W1, 65.0%;W7,
55.9%; type 2 diabetes: W1, 55.7%, W7, 41.1%) among patients diagnosed with hypertension.
Conclusions/interpretation In LMICs, real-world data suggest improvement in screening and treatment for kidney disease in
patients with type 1 and type 2 diabetes attending non-nephrology clinics. This was accompanied by decreasing proportions of
patients with microalbuminuria and proteinuria, with fewer patients who reported receiving dialysis over a 12-year period.
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ARB Angiotensin II receptor blocker
CKD Chronic kidney disease
CRF Case report form
ESKD End-stage kidney disease
GLP-1 RA Glucagon-like peptide 1 receptor agonist
IDMPS International Diabetes Management
Practices Study
ISN International Society of Nephrology
LMIC Low-to-middle-income country
OGLD Oral glucose-lowering drug
RASi Renin–angiotensin system inhibitor
SGLT2i Sodium–glucose cotransporter-2 inhibitor
W Wave
Introduction
The global burden of kidney disease is rising along with an
increasing prevalence of diabetes, the latter being a leading
cause of kidney disease. Between 1990 and 2016, the global
prevalence of chronic kidney disease (CKD) had increased by
87%, from 147.6 million to 275.9 million, while deaths due to
CKD increased by 98%, from 0.6 million to 1.2 million [1]. In
approximately 40% of patients with CKD, the CKD is directly
attributed to diabetes, [1] which often coexists with other risk
factors, such as hypertension [2]. In the USA National Health
and Nutrition Examination Survey (NHANES) conducted
between 2009 and 2014, approximately 25% of patients with
diabetes had CKD [3]. Development of CKD increases the
risk of hypoglycaemia and treatment complexity in patients
with diabetes [4, 5]. Additionally, CKD and diabetes are inde-
pendent risk factors for CVD [6, 7].
Regular screening to detect kidney disease can prompt early
intervention which can reduce the incidence of end-stage kidney
disease (ESKD) and healthcare costs, and increase ESKD-free
survival [8, 9]. The USNational Kidney Foundation recommend
that patients with diabetes should undergo screening for kidney
disease annually, beginning 5 years after diagnosis of type 1
diabetes and at diagnosis of type 2 diabetes [10]. Annual screen-
ing should include measurements of urinary albumin/creatinine
ratio (ACR) to detect microalbuminuria and serum creatinine for
calculation of eGFR [10]. The National Institute for Health and
Care Excellence in the UK recommends increased frequency of
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screening in patients with or at risk of CKD, or with worsening
kidney function (based on eGFR and/or ACR measurements)
[11].
The prevalence and outcomes of kidney disease have
strong socioeconomic determinants. The sociodemographic
index of a country is based on average income per person,
educational attainment and total fertility rate. In countries with
a high sociodemographic index, the age-standardised preva-
lence of CKD has been shown to be lower than in countries
with a low sociodemographic index [1]. In this global epidem-
ic of diabetes where low-to-middle-income countries (LMICs)
are hit hardest with the dual burden of diabetes and kidney
disease [2], there are limited data on the pattern of screening,
prevalence, treatment and control of kidney disease for both
type 1 and type 2 diabetes to inform practice and policies.
The International Diabetes Management Practices Study
(IDMPS) is an ongoing worldwide observational survey that
describes the clinical profiles and management of patients
receiving outpatient care mainly by internal medicine physi-
cians and endocrinologists in LMICs [12]. Data were collect-
ed in seven successive waves between 2005 (Wave [W]1) and
2017 (W7). In this analysis, we examined screening, prevalence,
treatment and control of kidney disease (microalbuminuria,
proteinuria) in patients with type 1 or type 2 diabetes during a
12 year period.
Methods
Study design The IDMPS is an ongoing, non-interventional
international study documenting diabetes care practices
involving more than 80,000 patients with diabetes managed
by over 6000 physicians living across 49 LMICs. Between
2005 and 2017, real-world data were collected in seven indi-
vidual waves conducted in different regions and countries
(electronic supplementary material [ESM] Table 1). Each
wave comprised a 2 week cross-sectional study when consec-
utive patients were recruited from participating clinics.
Primary care and specialist physicians (i.e. internal medi-
cine specialists, diabetologists, endocrinologists) who were
familiar with the use of insulin were invited to enrol their first
five patients with type 1 diabetes and ten patients with type 2
diabetes (male or female) who attended their clinics during the
2 week recruitment period. Clinical data were collected and
completed by the physicians using standardised case report
forms (CRFs). Physicians recorded whether the patient had
been screened for kidney disease within the 12 months prior
to the study visit, and the frequency of screening. Details of
setting/physicians who performed the screening were not
recorded.
The first patient in W1 was enrolled on 31 January 2004
and the last patient completed W7 on 12 October 2016. The
study design and reporting format were in accordance with
STROBE (STrengthening of the Reporting of OBservational
studies in Epidemiology) guidelines. Ethical approval was
obtained from institutional review boards in each country
and the study was conducted in accordance with the
Declaration of Helsinki. All patients provided written
informed consent.
Participants Patients with type 1 or type 2 diabetes over the
country-specific adult legal age were eligible to participate.
Exclusion criteria included concomitant participation in
another clinical study, participation in a previous wave of
IDMPS, or current receipt of temporary insulin therapy due
to gestational diabetes, pancreatic cancer or surgery.
Outcome measurements The primary outcome of this analy-
sis was the proportion of patients who underwent screening
for kidney disease within the 12 months prior to each study
visit, and the prevalence of kidney disease over a 12 year
period. Participating physicians completed the CRFs using
simple coding of Yes/No at their discretion. Outcomes includ-
ed the presence of microalbuminuria (determined by labora-
tory measurement or desktop machines prior to this study) or
proteinuria (determined by dipstick method prior to this
study). Urinary ACR values were not recorded and data on
eGFR were collected in W7 only with CKD (stage 3) defined
as eGFR <60 ml min−1 [1.73 m]−2. Additionally, physicians
were asked to document diagnosed hypertension and
dyslipidaemia, reported dialysis treatment and presence of
microvascular (e.g. retinopathy, visual impairment and senso-
ry neuropathy) and macrovascular (e.g. stroke, ischaemic
heart disease, myocardial infarction, acute coronary syndrome
and revascularisation procedures) complications. The last
HbA1c value and BP in the last 12 months, body weight/
height measured during the clinic visit, as well as current
treatments, were recorded.
Statistical analysis The sample size of IDMPSwas determined
for each country based on the primary objective of IDMPS,
which aimed to assess the therapeutic management of patients
with type 2 diabetes and establish the proportion of those
patients with insulin-treated type 2 diabetes, assuming that
insulin was the least prescribed therapy for type 2 diabetes.
For an estimated proportion of 20% with a precision of 4%
and a 95% CI of 16–24%, a sample size of 384 patients would
be required from each country. For a prevalence of 5% with a
precision of 1% and a 95% CI of 4–6%, a sample size of
1825 patients would be required. The actual number of
patients recruited from each country varied according to the
estimated prevalence of patients with insulin-treated type 2
diabetes in that country (ESM Methods). Physicians experi-
enced in prescribing insulin therapy were selected randomly
after stratification based on specialty (primary care doctors or
endocrinologists). The number of participating physicians
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recruited was based on the country-specific estimated patient
sample size required.
The eligible population comprised all patients with no
missing data concerning diabetes treatment. Missing data
were not imputed, except for day or month of birth, which
were set to ‘15’ or ‘June’, respectively. Categorical variables
were presented using counts and percentages and continuous
variables as means and SDs. Due to the descriptive nature of
the study and the fact that no formal hypothesis was tested,
descriptive analyses were performed with no comparative
analyses or p values.
Results
Patient characteristics A total of 15,079 patients with type 1
diabetes and 66,088 patients with type 2 diabetes were includ-
ed in the seven waves of data collection. Patient demographics
and clinical characteristics are described in Table 1. Among
patients with type 2 diabetes, 42,171 (63.8%) were treated
with oral glucose-lowering drugs (OGLDs) alone, 7566 with
insulin alone (11.4%) and 14,529 (22.0%) with OGLDs plus
insulin. The distribution of participation in healthy diet and
exercise plans and use of OGLDs and insulin in each patient
group is shown in ESM Table 2. Patients with type 1 diabetes
were more likely to follow a healthy diet and exercise plan
than patients with type 2 diabetes. Metformin and sulfonyl-
ureas were the most common OGLDs. The use of glucagon-
like peptide 1 receptor agonists (GLP-1 RA) was recorded
fromW4 onwards and less than 3.0% of patients received this
drug between W4 and W7. The use of sodium–glucose
cotransporter-2 inhibitors (SGLT2i) was captured only in
W7. A total of five patients (3.4%, n = 149) with type 1 diabe-
tes and 21 patients (1.0%, n = 2125) with type 2 diabetes were
treated with an SGLT2i. Insulin was administered to every
patient with type 1 diabetes, with 52–68% treated with a
basal–bolus regimen and 17–24% treated with a premix insu-
lin regimen. In patients with type 2 diabetes, insulin use varied
between 30% and 41% acrossW1 toW7. In patients with type
1 or type 2 diabetes, meanHbA1c was similar across all waves,
and glycaemic target achievement (<53 mmol/mol [<7%])
remained suboptimal (20.7–38.0%) over time (Table 1).
Mean BMI was similar over time in type 1 diabetes (W1,
23.4 [SD 3.7] kg/m2; W7, 24.7 [4.6] kg/m2) and increased
over time with type 2 diabetes (W1, 27.1 [4.8] kg/m2; W7,
29.8 [5.5] kg/m2) with a mean difference (95% CI) of 2.68
(2.52, 2.85) kg/m2 (Table 1).
Screening for kidney disease Between W2 and W3 (2006 and
2008), screening for kidney diseasemarkedly increased followed
by a plateau thereafter in both patients with type 1 and type 2
diabetes (Fig. 1a). A similar increase was found in patients with
type 2 diabetes when divided by therapy type (Fig. 1b). A greater
proportion of patients with type 1 diabetes were screened vs
those with type 2 diabetes. Among patients with type 2 diabetes,
those treated with insulin were more likely to be screened. By
W7, over 80% of patients in both groups had undergone screen-
ing in the previous 12 months.
In both patients with type 1 and type 2 diabetes, the propor-
tion with microalbuminuria/proteinuria decreased between
W1 and W7 (2005–2017) with the greatest decrease observed
betweenW1 andW3 (Fig. 2a, c). A similar pattern was seen in
patients with type 2 diabetes irrespective of therapy type.
Throughout the seven waves, patients with type 2 diabetes
treated solely with OGLDs had the lowest proportion of
microalbuminuria/proteinuria and those treated with insulin
alone had the highest (Fig. 2b, d).
Overall, 0.2–1.5% of patients with type 1 or type 2 diabetes
were recorded by the participating physicians (general practi-
tioners, internal medicine specialists, endocrinologists or diabe-
tologists) as requiring dialysis during all waves (Table 1). Based
on eGFR data collected in W7, a greater proportion of patients
with type 2 diabetes had CKD stage 3 (eGFR <60 ml min−1
[1.73 m]−2) than patients with type 1 diabetes (21.6% vs
10.5%, respectively) (Table 1 and ESM Table 3). An eGFR of
<15 ml min−1 [1.73 m]−2, indicative of ESKD (CKD stage 5),
was reported in 2.6%of patientswith type 1 diabetes and 2.3%of
patients with type 2 diabetes (ESM Table 3).
Hypertension and associated treatments The proportion of
patients with diagnosed hypertension was similar over time in
patients with type 1 diabetes (22.7% in W1; 19.9% in W7). The
proportion of patients with type 2 diabetes diagnosedwith hyper-
tension increased over time (60.9% inW1; 66.2% inW7) (ESM
Table 4). Among patients diagnosed with hypertension, the use
of ACE inhibitors (ACEi) was highest inW1 (type 1 diabetes,
65.0%; type 2 diabetes, 55.7%) but had fallen by W7
(type 1 diabetes, 55.9%; type 2 diabetes, 41.1%).
Increasing use of angiotensin II receptor blockers
(ARBs) was evident in subsequent waves (type 1 diabe-
tes, 18.0% in W1; 30.6% in W7; type 2 diabetes, 24.2%
in W1; 43.6% in W7). During this period, statin use
among patients diagnosed with dyslipidaemia also
increased for patients with type 1 diabetes (W1,
77.7%; W7, 90.7%) and type 2 diabetes (W1, 78.6%;
W7, 94.7%; ESM Table 4).
Discussion
In this survey with real-world data from 81,167 patients with
type 1 and type 2 diabetes recruited from 49 LMICs between
2005 and 2017, we have observed increased screening for
kidney disease, with the greatest improvement occurring
between 2005 and 2008. This was accompanied by declining
proportions of patients with kidney disease (microalbuminuria,
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proteinuria or reported dialysis treatment). Of note, the preva-
lence of microalbuminuria, proteinuria, and microvascular and
macrovascular complications decreased sharply between W1
(2005) and W3 (2008) and then plateaued; minor fluctuations
were subsequently seen in the prevalence of microalbuminuria,
although the prevalence of proteinuria remained low. While
glycaemic control and diagnosis of hypertension did not
improve over time, the use of statins among patients diagnosed
with dyslipidaemia and renin–angiotensin system inhibitors
(RASis) among patients diagnosed with hypertension
increased. The renoprotective effects of RASis in type 1 and
type 2 diabetes have been confirmed in large scale randomised















Type 1 diabetes (N=15,079) (n=1845) (n=3507) (n=2337) (n=958) (n=2789) (n=1643) (n=2000)
Age, years 36.42±13.98 35.24±13.75 35.44±14.72 34.89±14.78 33.73±13.02 33.88±12.54 33.97±12.32
Male 923 (50.4) 1642 (48.3) 1130 (49.2) 444 (46.7) 1366 (49.0) 805 (49.0) 976 (48.8)
BMI, kg/m2 23.41±3.72 24.20±4.48 24.36±4.56 25.33±4.82 24.18±4.66 24.69±4.58 24.73±4.61
Systolic BP, mmHg 121.99±17.07 121.26±16.46 119.42±16.04 118.84±13.92 120.36±14.90 121.55±15.81 121.07±14.56
Diastolic BP, mmHg 75.48±9.55 74.93±9.85 73.89±9.56 74.84±9.35 75.00±9.44 75.67±9.46 75.31±9.42
Duration of diabetes, years 11.44±9.16 11.62±9.37 12.31±9.68 13.38±10.42 11.79±9.23 12.00±9.18 13.05±9.88
Last known HbA1c,
mmol/mol 67.20±21.64 69.49±23.94 67.31±22.63 68.73±22.63 68.84±22.63 68.51±20.44 68.18±20.55
% 8.30±1.98 8.51±2.19 8.31±2.07 8.44±2.07 8.45±2.07 8.42±1.87 8.39±1.88
HbA1c <53 mmol/mol (<7%) 349 (25.5) 637 (23.1) 487 (25.7) 193 (22.9) 565 (22.7) 312 (20.7) 403 (21.8)
Microalbuminuria 400 (27.1) NA 344 (14.7) 152 (15.9) 524 (18.8) 296 (18.6) 267 (13.8)
Proteinuria 239 (14.2) 704 (22.2) 204 (8.7) 85 (8.9) 290 (10.4) 137 (8.6) 159 (8.2)
CKD NA NA NA NA NA NA 159 (10.5)
Dialysis NA 49 (1.4) 34 (1.5) 14 (1.5) 24 (0.9) 8 (0.5) 6 (0.3)
Microvascular complicationsa 958 (60.1) 1505 (47.0) 829 (35.5) 370 (38.6) 1336 (49.4) 903 (56.8) 924 (47.7)
Macrovascular complicationsb 220 (12.4) 307 (9.2) 184 (7.9) 90 (9.4) 275 (10.2) 172 (10.8) 115 (5.9)
Type 2 diabetes (N=66,088) (n=9918) (n=17,232) (n=12,210) (n=5343) (n=9603) (n=5479) (n=6303)
Age, years 58.05±11.51 58.18±11.79 57.70±11.84 58.42±11.94 57.58±11.20 57.33±10.68 57.19±11.09
Male 4749 (48.1) 7993 (47.8) 5490 (45.9) 2421 (45.7) 4486 (46.7) 2431 (44.4) 3012 (47.8)
BMI, kg/m2 27.12±4.80 28.45±5.26 28.97±5.53 29.75±5.49 29.60±5.50 30.20±5.67 29.80±5.53
Systolic BP, mmHg 134.47±19.26 133.32±18.57 129.87±17.19 129.66±17.48 133.21±17.20 133.75±17.02 134.07±16.74
Diastolic BP, mmHg 80.81±10.37 79.75±10.52 78.45±9.79 78.52±10.05 80.45±10.03 80.67±10.32 80.79±9.86
Duration of diabetes, years 8.25±7.08 8.55±7.83 8.83±7.74 9.09±8.10 8.71±7.32 9.26±7.13 9.76±7.38
Last known HbA1c,
mmol/mol 61.51±19.46 63.15±21.10 62.28±21.31 62.61±20.22 64.36±20.99 64.14±19.46 64.57±20.66
% 7.78±1.78 7.93±1.93 7.85±1.95 7.88±1.85 8.04±1.92 8.02±1.78 8.06±1.89
HbA1c <53 mmol/mol (<7%) 2168 (36.0) 4275 (35.2) 3446 (38.0) 1625 (37.1) 2658 (31.8) 1449 (29.4) 1716 (30.1)
Microalbuminuria 1713 (24.5) NA 1540 (12.6) 773 (14.5) 1530 (15.9) 870 (16.4) 735 (11.9)
Proteinuria 1331 (15.6) 3128 (21.1) 1130 (9.3) 453 (8.5) 829 (8.6) 400 (7.5) 471 (7.6)
CKD NA NA NA NA NA NA 1058 (21.6)
Dialysis NA 146 (0.9) 128 (1.0) 51 (1.0) 35 (0.4) 14 (0.3) 15 (0.2)
Microvascular complicationsa 5199 (65.1) 7380 (49.2) 4732 (38.8) 2271 (42.5) 4583 (49.6) 2895 (54.5) 2988 (48.4)
Macrovascular complicationsb 2560 (28.1) 3929 (24.4) 2345 (19.2) 1088 (20.4) 2103 (22.8) 1311 (24.7) 990 (16.0)
Values are mean ± SD or n (%). All complications were reported by physicians (Y/N)
Percentages were calculated for patients with available data; these varied by each category/wave
CKD defined as eGFR <60 ml min-1 [1.73 m]-2
a Retinopathy, visual impairment, sensory neuropathy, microalbuminuria, proteinuria and dialysis
b Stroke and ischaemic heart disease, myocardial infarction or acute coronary syndrome or history of revascularisation
NA, not available
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clinical trials [13–15]. Despite these improvements, 12–14% of
patients had microalbuminuria and approximately 8% had
proteinuria in 2017. These care gaps call for further treatment
intensification and improvement in self-management.
These results align with those from the 2019 International
Society of Nephrology (ISN) Global Kidney Health Atlas
which reported a global screening rate for kidney disease of
90–100% [16]. Among patients with diabetes, the estimated
proportion of patients screened for kidney disease was 86% in
LMICs, 95% in upper-middle-income countries and 98% in
high-income countries [16].
In our analysis, patients with type 1 diabetes were more
likely to be screened (74–91%) than those with type 2 diabetes
(63–89%). Interestingly, patients with type 1 diabetes were
more likely to follow a healthy diet than those with type 2
diabetes, suggesting possible care disparity between type 1
and type 2 diabetes. However, patients with type 2 diabetes
treated with OGLDs plus insulin or insulin alone were more
likely to have microalbuminuria than those with type 1 diabe-
tes (Fig. 2a). This was possibly due to the older age and higher
prevalence of diagnosed hypertension in patients with type 2
diabetes compared with those with type 1 diabetes. Among
patients with type 2 diabetes, those treated with insulin were
more likely to be screened than those who were not. This
suggests that physicians recognise the high risk profile for
patients treated with insulin, which is characterised by worse
glycaemic control, more complications and longer disease
duration vs those treated with OGLDs [17].
In 2017 (W7), when eGFR results were captured, approx-
imately one in five patients with type 2 diabetes treated with
OGLDs alone, one in three patients with insulin-treated type 2
diabetes and one in ten patients with type 1 diabetes had CKD
stage 3 or above. InW7, 2–5% of patients had ESKD based on
eGFR data. In comparison, 0.2–1.5% reported dialysis in all
waves, suggesting possible under-reporting or non-
commencement of dialysis despite the presence of ESKD.
In our results, the prevalence of microalbuminuria (type 1
diabetes: 13.8–27.1%; type 2 diabetes: 11.9–24.5%) was
higher than that reported in a meta-analysis of 71 observation-
al studies from 30 countries (predominantly high-income
countries, with more than a third from the USA) [18]. In this
meta-analysis, the prevalence of microalbuminuria was
1.3–3.8% in patients with type 1 diabetes and 3.8–12.7% in
patients with type 2 diabetes [18]. However, differences in
study design, populations and settings could lead to marked
variations in these results. To this end, the proportions of
patients with microalbuminuria/proteinuria in our study was
similar to another cross-sectional study conducted in the USA
between 2009 and 2014 with documented urinary ACR
measurements [3].
Due to the silent nature of kidney disease, screening by
blood and urine tests is necessary to inform medication use.
Screening for CKD has been shown to reduce the incidence of
ESKD and healthcare costs [8, 9]. By reducing multiple risk
factors including high BP, lipids, HbA1c and use of organ-
protective drugs such as statins and RASis, the rate of decline
of eGFR can be attenuated [8, 9]. In this light, the US National
Kidney Foundation recommends the implementation of a
country-wide screening programme of patients with diabetes
to detect kidney disease at least once yearly using several
diagnostic methods [10]. These screening programmes are




































































































































T2D OGLD + insulin
T2D insulin only
ba
Fig. 1 Screening for kidney disease in (a) patients with type 1 and type 2 diabetes over time and (b) patients with type 2 diabetes divided by therapy type.
Percentages were calculated for patients with available data; these varied by each category/wave. T1D, type 1 diabetes; T2D, type 2 diabetes
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and have huge public health benefits [19, 20]. Given the high
prevalence of kidney disease in LMICs, which have the least
capacity to provide expensive treatment for ESKD including
dialysis, increased investments to detect and treat kidney
disease early should be a policy priority in LMICs [9].
Many patients in LMICs first present to clinical practice
with advanced stages of kidney disease, sometimes requiring
dialysis at first presentation [21]. In LMICs, governments
often provide essential medical coverage mainly for acute
illnesses or hospitalisation. In a survey of 130 countries affil-
iated with the ISN, none of the low-income and lower-middle-
income countries reported implementation of a fully
subsidised screening and care programme for patients with
non-dialysis CKD [19]. Hence, despite the potential
cardiovascular–renal protective effects of statins [22] and
RASis [13, 14, 23], many patients had to pay out of pocket
for these screening tests and preventive medications. In a







































































































































































































































T2D OGLD + insulin
T2D insulin only
Fig. 2 Microalbuminuria in patients with type 1 and type 2 diabetes (a)
and in patients with type 2 diabetes divided by therapy type (b); protein-
uria in patients with type 1 and type 2 diabetes (c) and in patients with
type 2 diabetes divided by therapy type (d). Percentages were calculated
for patients with available data; these varied by each category/wave.
Microalbuminuria data were not available in W2. T1D, type 1 diabetes;
T2D, type 2 diabetes
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and 2012 including LMICs (China, India, The Philippines and
Vietnam) and high-income countries/areas (Hong Kong,
South Korea and Taiwan), suboptimal control of cardiometa-
bolic risk factors and low usage of statins and RASis were
major risk factors for CKD [24].
In this analysis of real-world data, approximately 20% of
patients with type 1 diabetes and approximately 60% of
patients with type 2 diabetes were diagnosed with hyperten-
sion. Among these diagnosed patients, over 90% received
antihypertensive therapies, including RASis. Over 77% of
patients diagnosed with dyslipidaemia received statins across
all waves. Both of these treatments have been shown to
prevent or delay onset of CKD including ESKD and death
in patients with type 2 diabetes [13, 14, 22, 23]. In a separate
analysis of the IDMPS dataset, we reported declining propor-
tions of patients with type 2 diabetes with microvascular and
macrovascular complications accompanied by increasing use
of statins and RASis (predominantly due to an increase in
ARBs) (Ramachandran A, Lavalle F, Aschner P, et al, unpub-
lished results).
Better control of BP and lipids is expected to reduce the
incidence of CVD. However, ageing and increasing survival
along with suboptimal glycaemic control and earlier onset of
diabetes will continue to escalate the burden of CKD and
ESKD, as reported in the USA [20]. Control of multiple risk
factors, including optimising glycaemic and BP control, has
been shown to reduce the risk of microvascular and
macrovascular morbidity, ESKD and premature death [25,
26]. In our previous IDMPS reports, we reported suboptimal
and worsening glycaemic control in patients with type 2
diabetes over a 12-year period, despite increasing prescrip-
tions of insulin [17]. The use of GLP-1 RA and SGLT2i has
been shown to confer cardiovascular–renal protection [27],
although the use of these new medications was low in these
LMICs. However, our previous IDMPS data indicated asso-
ciations between good glycaemic control and self-monitoring
of blood glucose and patient education, as well as reduced
odds of complications and utilisation of healthcare resources
[28–30]. Given the size of the problems of diabetes and
kidney disease, policy and system changes are needed to raise
physician awareness and maximise their efforts to reduce
multiple risk factors while empowering patients to self-
manage their diabetes and thus reduce the burden of kidney
disease.
The strength of this study is the large sample size with
global representation outside Western Europe and North
America where data are needed to inform practice and poli-
cies. The main limitations include its observational nature
with physician-reported performance of screening procedure
without record of laboratory results. We did not record the
setting and physicians who performed screening for kidney
disease (e.g. general practitioners or specialists including
endocrinologists or nephrologists) in the previous 12 months.
The distribution of participating countries varied between
waves, which might influence the trends over time, with fewer
LMIC countries from Africa, Eurasia and the Middle East
represented in the earlier waves. In many LMICs, patients
may need to pay out of pocket for these screening tests which
might be performed in other clinics or laboratories, making it
logistically challenging to verify the results. We relied on
physicians to report the presence of microvascular and
macrovascular complications which might be influenced by
recall bias, subjective interpretation or incomplete reporting.
In 2015, the National Kidney Foundation guidelines recom-
mended annual measurement of eGFR [10] which was included
as a variable in W7. Prior to that, we used microalbuminuria and
proteinuria as surrogates for kidney disease.We also do not have
data regarding the use of ACEi and ARBs in patients without a
diagnosis of hypertension. Due to the cross-sectional nature of
each survey, we could not infer any causal relationship between
the increasing prevalence of screening procedures and declining
prevalence of kidney disease, and because of differences in
healthcare systems and practices, these changes only reflected
an overall pattern of variation between sites and waves. Self-
selection also limited generalisability of these results since
patients with advanced or suboptimally controlled diabetes may
be more likely to seek medical advice, which might lead to
overestimation of the prevalence of complications. On the other
hand, since the majority of participating physicians were internal
medicine physicians, family doctors and endocrinologists, this
might explain the low prevalence of patients receiving dialysis
reported in the present analysis, as these patients are more likely
to be seen by nephrologists.
Briefly, in LMICs, between 2002 and 2017, increasing
proportions of patients with type 1 and type 2 diabetes attend-
ing outpatient clinics in LMICs were screened for kidney
disease. This was accompanied by increasing use of statins
and RASis and decreasing prevalence of albuminuria/
proteinuria over time. Despite these encouraging observa-
tions, in the most recent wave (2017), approximately 15% of
patients had not been screened while 12–14% had
microalbuminuria and approximately 8% had proteinuria.
Given the persistently poor glycaemic control and lack of
improvement in diagnosed hypertension, system-wide chang-
es are needed to improve capacity and access for screening
and control of multiple risk factors in order to reduce the
burden of kidney disease in LMICs.
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